Search

Your search keyword '"Sunil Bhat"' showing total 212 results
Start Over Author "Sunil Bhat"
212 results on '"Sunil Bhat"'

1. Retinoblastoma with and without Extraocular Tumor Extension

Author

Swathi Kaliki, MD, Vijitha S. Vempuluru, MD, Ido Didi Fabian, MD, Elhassan Abdallah, MD, Shehu U. Abdullahi, MD, Rula A. Abdulqader, MD, Aminatu A. Abdulrahaman, MD, Sherif Abouelnaga, MD, Dupe S. Ademola-Popoola, FMCOph, FWACS, Adedayo Adio, FWACS, Mahmoud A. Afifi, MD, Armin R. Afshar, MD, Priyanka Aggarwal, MD, Ada E. Aghaji, FMCOph MSc, Alia Ahmad, MRCPCH UK, Marliyanti N.R. Akib, MD, Adeseye M. Akinsete, MBBS, Lamis Al Harby, MD, Saleh A. Al Mesfer, MD, Mouroge H. Al Ani, MD, Silvia Alarcón Portabella, MD, Safaa A.F. Al-Badri, MD, Ana Patricia A. Alcasabas, MD, Saad A. Al-Dahmash, MD, Amanda Alejos, MD, Ernesto Alemany-Rubio, MD, Amadou I. Alfa Bio, MD, Yvania Alfonso Carreras, MD, Christiane E. Al-Haddad, MD, Hamoud H.Y. Al-Hussaini, MD, MSc, Amany M. Ali, MD, Donjeta B. Alia, MD, Mazin F. Al-Jadiry, MD, Usama Al-Jumaly, MD, Hind M. Alkatan, MD, Charlotta All-Eriksson, MD, PhD, Ali A.R.M. Al-Mafrachi, FIBMS, Argentino A. Almeida, MD, Khalifa M. Alsawidi, MD, Athar A.S.M. Al-Shaheen, MD, Entissar H. Al-Shammary, MD, Doreen Amankwaa-Frempong, MBChB, Primawita O. Amiruddin, MD, Inggar Armytasari, MD, Nicholas J. Astbury, FRCS, FRCOphth, Hatice T. Atalay, MD, Eda Ataseven, MD, La-ongsri Atchaneeyasakul, MD, Rose Atsiaya, OCO, Rudolf Autrata, MD, PhD, Julia Balaguer, MD, PhD, Ruhengiz Balayeva, PhD, Honorio Barranco, MD, PhD, Paulina Bartoszek, MD, Katarina Bartuma, MD, PhD, Covadonga Bascaran, MD, MSc, Nikolaos E. Bechrakis, MD, Maja Beck Popovic, MD, Ainura S. Begimkulova, MD, Sarra Benmiloud, MD, Rokia C. Berete, MD, PhD, Jesse L. Berry, MD, Anirban Bhaduri, MD, Sunil Bhat, MBBS, MD, Arpita Bhattacharyya, MD, Eva M. Biewald, MD, Elaine Binkley, MD, Sharon Blum, MD, Nadia Bobrova, MD, H. Culver Boldt, MD, Maria Teresa B.C. Bonanomi, MD, PhD, Gabrielle C. Bouda, MD, Hédi Bouguila, MD, PhD, Rachel C. Brennan, MD, Bénédicte G. Brichard, MD, PhD, Jassada Buaboonnam, MD, Aléine Budiongo, MD, Matthew Burton, FRCOphth, Patricia Calderón-Sotelo, MD, Doris A. Calle Jara, MD, Jayne E. Camuglia, FRANZCO, Miriam R. Cano, MD, MSc, Michael Capra, FRCPI, Shani Caspi, MD, Nathalie Cassoux, MD, PhD, Guilherme Castela, MD, Luis Castillo, MD, Jaume Català-Mora, MD, PhD, Isabel Caviedes, MD, Arthika Chandramohan, MD, Guillermo L. Chantada, MD, PhD, Shabana Chaudhry, MD, Bhavna Chawla, MD, Wensi Chen, MD, Faraja S. Chiwanga, MSc, Tsengelmaa Chuluunbat, MD, PhD, Krzysztof Cieslik, MD, Antony Clark, FRANZCO, Ruellyn L. Cockcroft, MB ChB , M Med Paed, Codruta Comsa, MD, Maria G. Correa Llano, MD, Timothy W. Corson, PhD, Line Couitchere, MD, Kristin E. Cowan-Lyn, MD, MBBS, Monika Csóka, MD, PhD, Wantanee Dangboon, MD, Anirban Das, MD, Pranab Das, MD, Sima Das, MS, Jacquelyn M. Davanzo, BSN, BSPH, Alan Davidson, MBChB, MPhil, Sonia De Francesco, MD, Patrick De Potter, MD, PhD, Karina Q. Delgado, MD, PhD, Hakan Demirci, MD, Laurence Desjardins, MD, Rosdali Y. Diaz Coronado, MD, Helen Dimaras, PhD, Andrew J. Dodgshun, M Phil, Carla R. Donato Macedo, MD, Monica D. Dragomir, MD, PhD, Yi Du, MD, Magritha Du Bruyn, MD, Johannes P. Du Plessis, MMed (Paed), Gagan Dudeja, MBBS, MS, Katrin Eerme, MD, I Wayan Eka Sutyawan, MD, Asmaa El Kettani, MD, Amal M. Elbahi, MD, James E. Elder, MBBS, Alaa M. Elhaddad, MD, PhD, Moawia M.A. Elhassan, MD, Mahmoud M. Elzembely, MD, Connor Ericksen, MD, Vera A. Essuman, FWACS, Ted Grimbert A. Evina, MD, Ifeoma R. Ezegwui, FMCOph, FWACS, FAEH, Zehra Fadoo, MBBS, Adriana C. Fandiño, MD, Mohammad Faranoush, MD, Oluyemi Fasina, FWACS, Delia D.P.G. Fernández, MSc, Ana Fernández-Teijeiro, MD, PhD, Allen Foster, FRCOphth, Shahar Frenkel, MD, PhD, Ligia D. Fu, MD, Soad L. Fuentes-Alabi, MD, MPH, Juan L. Garcia, MSc, David García Aldana, MD, Henry N. Garcia Pacheco, MD, Jennifer A. Geel, MBChB, MMed, Fariba Ghassemi, MD, Ana V. Girón, MD, Marco A. Goenz, MD, Aaron S. Gold, OD, Hila Golberg, MD, Glen A. Gole, MD, FRANZCO, Nir Gomel, MD, Efren Gonzalez, MD, Graciela Gonzalez Perez, MD, Liudmira González-Rodríguez, MD, Malka Gorfine, PhD, Jaime Graells, MD, Pernille A. Gregersen, MD, Nathalia D.A.K. Grigorovski, MD, Koffi M. Guedenon, MD, D Sanjeeva Gunasekera, MD, Ahmet K. Gündüz, MD, Himika Gupta, MD, Sanjiv Gupta, MS, Vineeta Gupta, MD, Theodora Hadjistilianou, MD, Patrick Hamel, MD, Syed A. Hamid, FCPS, Norhafizah Hamzah, MSc, Eric D. Hansen, MD, J William Harbour, MD, M. Elizabeth Hartnett, MD, Murat Hasanreisoglu, MD, Sadiq Hassan, MD, FWACS, Shadab Hassan, FRCS, FCPS, Wojciech Hautz, MD, Huda A. Haydar, CHD, Stanislava Hederova, MD, Laila Hessissen, MD, Hoby Lalaina, MD, Suradej Hongeng, MD, Diriba F. Hordofa, MD, G. Baker Hubbard, MD, Marlies Hummlen, MD, Kristina Husakova, MD, Allawi N. Hussein Al-Janabi, MD, Affiong A. Ibanga, MB.BCh, FMCOph, Russo Ida, MD, Vesna R. Ilic, MD, Ziyavuddin Islamov, MD, Vivekaraj Jairaj, DNB, Teyyeb A. Janjua, MD, FCPS, FRCSEd, Irfan Jeeva, FRCOphth, Xunda Ji, MD, Dong Hyun Jo, MD, PhD, Michael M. Jones, MD, PhD, FRANZCO, Theophile B. Amani Kabesha, MD, PhD, Rolande L. Kabore, MD, Abubakar Kalinaki, MD, Pius Kamsang, MD, Mehmet Kantar, MD, Noa Kapelushnik, MD, Tamar Kardava, PhD, Rejin Kebudi, MD, Jonny Keomisy, MD, Tomas Kepak, MD, Petra Ketteler, MD, Zohora J. Khan, MD, Hussain A. Khaqan, MD, Vikas Khetan, FRCS, FACS, Alireza Khodabande, MD, Zaza Khotenashvili, MD, Jonathan W. Kim, MD, Jeong Hun Kim, MD, PhD, Hayyam Kiratli, MD, Tero T. Kivelä, MD, Artur Klett, MD, PhD, Irem Koç, MD, Jess Elio Kosh Komba Palet, MD, Dalia Krivaitiene, MD, PhD, Mariana Kruger, Mmed Paed, PhD, Kittisak Kulvichit, MD, Mayasari W. Kuntorini, MD, Alice Kyara, BA, Geoffrey C. Lam, FRANZCO, Scott A. Larson, MD, Slobodanka Latinović, MD, PhD, Kelly D. Laurenti, MD, Yotam Lavi, MD, PhD, Alenka Lavric Groznik, MD, Amy A. Leverant, MD, Cairui Li, MD, Kaijun Li, MD, Ben Limbu, MD, Chun-Hsiu Liu, MD, Quah Boon Long, FRCS (Ed), MMed ( Ophth), FAMS, Juan P. López, MD, Robert M. Lukamba, MD, Sandra Luna-Fineman, MD, Delfitri Lutfi, MD, Lesia Lysytsia, MD, Shiran Madgar, MD, George N. Magrath, MD, Amita Mahajan, MD, Puja Maitra, MD, Erika Maka, MD, Emil K. Makimbetov, MD, Azza M.Y. Maktabi, MD, Carlos Maldonado, MD, Ashwin Mallipatna, MD, Rebecca Manudhane, MD, Lyazat Manzhuova, MD, Nieves Martín Begue, MD, PhD, Sidra Masud, MBBS, Ibrahim O. Matende, MD, M. Med (Oph), Clarissa C.D.S. Mattosinho, MD, Marchelo Matua, BAPH, Ismail Mayet, MD, Freddy B. Mbumba, MD, MMed Paed, John D. McKenzie, MD, Azim Mehrvar, MD, Aemero A. Mengesha, MD, Vikas Menon, MD, Gary John V.D.D. Mercado, MD, Marilyn B. Mets, MD, Edoardo Midena, MD, PhD, Audra Miller, MD, Divyansh K.C. Mishra, DNB, Furahini G. Mndeme, MD, Ahmed A. Mohamedani, FRCPath, Mona T. Mohammad, MD, FRCS, Annette C. Moll, MD, PhD, Margarita M. Montero, MD, Claude Moreira, MD, PhD, Prithvi Mruthyunjaya, MD, MHS, Mchikirwa S. Msina, MMed Ophth, Gerald Msukwa, MMed Ophth, Sangeeta S. Mudaliar, DNB Pediatric, Hassan Muhammad, MD, Kangwa I. Muma, MMed Ophth, FCOphth, Francis L. Munier, MD, Timothy G. Murray, MD, MBA, Kareem O. Musa, FWACS, FMCOphth, FICO, Asma Mushtaq, MD, Anne A. Musika, MD, Hamzah Mustak, MD, Tajudeen Mustapha, MBBS, FWACS, Okwen M. Muyen, MD, Khumo H. Myezo, Msc, Gita Naidu, MMed Paed, PhD, Natasha Naidu, MBCHB, FCS Ophthalmol, Akshay Gopinathan Nair, MD, Sundaram Natarajan, FRCS, Larisa Naumenko, MD, PhD, Paule Aïda Ndoye Roth, MD PhD, Yetty M. Nency, MD, Vladimir Neroev, MD, PhD, Yvonne Ng, MBChB ( Auckland) , FRANZCO, Marina Nikitovic, MD, PhD, Elizabeth D. Nkanga, FMCOph, Henry E. Nkumbe, MD, Marcel N. Numbi, MD, Kalle Nummi, MD, Murtuza Nuruddin, FRCS, Mutale Nyaywa, MD, MMed Ophth, FCOphth, Chinsisi Nyirenda, MD, Ghislaine Obono-Obiang, MD, Scott C.N. Oliver, MD, Joaquin Ooporto, MD, Miriam Ortega-Hernández, MD, Alexander Oscar, MD, Diego Ossandon, MD, Halimah Pagarra, MD, PhD, Vivian Paintsil, FWACP, Luisa Paiva, MD, Mahesh Shanmugam Palanivelu, FRCSED, Ruzanna Papyan, MD, Raffaele Parrozzani, MD, PhD, Claudia R. Pascual Morales, MD, Katherine E. Paton, MD, FRCSC, Jacob Pe'er, MD, Jesús Peralta Calvo, MD, Sanja Perić, MD, PhD, Chau T.M. Pham, MD, Remezo Philbert, MD, David A. Plager, MD, Pavel Pochop, MD, PhD, Rodrigo A. Polania, MD, Vladimir Polyakov, MD, Jimena Ponce, MD, Ali O. Qadir, MD, Seema Qayyum, FCPS, Jiang Qian, MD, Ardizal Rahman, MD, Purnima Rajkarnikar, MD, Rajesh Ramanjulu, MD, Aparna Ramasubramanian, MD, Marco A. Ramirez-Ortiz, MD, MPH, Jasmeen K. Randhawa, BA, Léa Raobela, MD, Riffat Rashid, MS, M. Ashwin Reddy, FRCOphth, Lorna A. Renner, FRCPCH (UK), David Reynders, MD, Dahiru Ribadu, FMCOph, Petra Ritter-Sovinz, MD, Anna Rogowska, MD, Duangnate Rojanaporn, MD, Livia Romero, MD, Soma R. Roy, DCO, Raya H. Saab, MD, Svetlana Saakyan, MD, PhD, Ahmed H. Sabhan, MD, Mandeep S. Sagoo, FRCS (Ed), Azza M.A. Said, MD, Rohit Saiju, MD, Beatriz Salas, MD, Sonsoles San Román Pacheco, MD, Gissela L. Sánchez, MD, Alma Janeth Sanchez Orozco, MD, Phayvanh Sayalith, MD, Trish A. Scanlan, MRCPI, MSc, Christoph Schwab, MD, Ahad Sedaghat, MD, Rachna Seth, DNB MNAMS, Mariana Sgroi, MD, Ankoor S. Shah, MD, PhD, Shawkat A. Shakoor, MS, Manoj K. Sharma, MD, Sadik T. Sherief, MD, Carol L. Shields, MD, David Sia, MB ChB, FRANZCO, Sorath Noorani Siddiqui, MD, Sidi Sidi cheikh, MD, PhD, Sónia Silva, MD, Arun D. Singh, MD, Usha Singh, MS, Penny Singha, MD, Rita S. Sitorus, MD, PhD, Alison H. Skalet, MD, PhD, Hendrian D. Soebagjo, MD, PhD, Tetyana Sorochynska, MD, PhD, Grace Ssali, MD, Andrew W. Stacey, MD, Sandra E. Staffieri, PhD, Erin D. Stahl, MD, David M. Steinberg, PhD, David K. Stones, MBChB, FCPaed, Caron Strahlendorf, MD, Maria Estela Coleoni Suarez, MD, Sadia Sultana, FCPS, Xiantao Sun, MD, Rosanne Superstein, MD, Eddy Supriyadi, MD, PhD, Supawan Surukrattanaskul, MD, Shigenobu Suzuki, MD, PhD, Karel Svojgr, MD, PhD, Fatoumata Sylla, MD, Gevorg Tamamyan, MD, PhD, Deborah Tan, MBBS, Alketa Tandili, MD, PhD, Jing Tang, MD, Fanny F. Tarrillo Leiva, MD, Maryam Tashvighi, MD, Bekim Tateshi, MD, PhD, Kok Hoi Teh, MD, Edi S. Tehuteru, MD, Luiz F. Teixeira, MD, Manca Tekavcic Pompe, MD, PhD, Abdullah Dahan M. Thawaba, MD, Tuyisabe Theophile, MSc, Helen Toledano, MBChB, Doan L. Trang, MD, Fousseyni Traoré, MD, Devjyoti Tripathy, MD, Samuray Tuncer, MD, Harba Tyau-Tyau, MD, Ali B. Umar, MD, FMCPath, Emel Unal, MD, Ogul E. Uner, BA, Steen F. Urbak, MD, PhD, Tatiana L. Ushakova, MD, Rustam H. Usmanov, MD, Sandra Valeina, MD, Paola Valente, MD, Milo van Hoefen Wijsard, MD, Jacqueline Karina Vasquez Anchaya, MD, Leon O. Vaughan, FRCS (Ed), Nevyana V. Veleva-Krasteva, MD, PhD, Nishant Verma, MD, Andi A. Victor, MD, PhD, Maris Viksnins, MD, Edwin G. Villacís Chafla, MD, Victor M. Villegas, MD, Victoria Vishnevskia-Dai, MD, Keith Waddell, DM, FRCP, FRCS, FRCOphth, Amina H. Wali, MD, FMCOph Nigeria, Yi-Zhuo Wang, MD, Nutsuchar Wangtiraumnuay, MD, FICO, Julie A. Wetter, MMed Rad Onc, FCRad Onc, Widiarti P. Riono, MD, Matthew W. Wilson, MD, Amelia D.C. Wime, MD, Atchareeya Wiwatwongwana, MD, Damrong Wiwatwongwana, MD, Charlotte Wolley Dod, MD, Emily S. Wong, FCOphth HK, FHKAM, Phanthipha Wongwai, MD, PhD, Si-qi Wu, MSc, Daoman Xiang, MD, PhD, Yishuang Xiao, MSc, Bing Xu, MD, Kang Xue, MD, Antonio Yaghy, MD, Jason C. Yam, FRCSEd, Huasheng Yang, MD, Jenny M. Yanga, MD, Muhammad A. Yaqub, MD, FCPS, FRCSEd, Vera A. Yarovaya, MD, Andrey A. Yarovoy, MD, PhD, Huijing Ye, MD, Roberto I. Yee, MD, Yacoub A. Yousef, MD, Putu Yuliawati, MD, Arturo M. López, MD, Ekhtelbenina Zein, MD, Yi Zhang, MD, PhD, Katsiaryna Zhilyaeva, MD, Nida Zia, MBBS, MCPS, Othman A.O. Ziko, MD, PhD, Marcia Zondervan, MBA, Sabrina Schlüter, MD, and Richard Bowman, FRCOphth

Subjects
External beam radiotherapy, Extraocular extension, Multimodal treatment, Retinoblastoma, Tumor, Ophthalmology, RE1-994
Abstract

Purpose: To study the treatment and outcomes of children with retinoblastoma (RB) with extraocular tumor extension (RB-EOE) and compare them with RB without extraocular tumor extension (RB-w/o-EOE). Design: Multicenter intercontinental collaborative prospective study from 2017 to 2020. RB-EOE cases included those with overt orbital tumor extension in treatment-naive patients. Cases with microscopic orbital extension detected postenucleation were excluded from the study. Participants: A total of 319 children with RB-EOE and 3116 children with RB-w/o-EOE. Intervention: Chemotherapy, enucleation, exenteration, radiotherapy. Main Outcome Measures: Systemic metastasis and death. Results: Of the 3435 RB patients included in this study, 309 (9%) were from low-income countries (LIC), 1448 (42%) from lower-middle income, 1012 (29%) from upper-middle income, and 666 (19%) patients from high-income countries. There was an inverse relationship between the percentage of RB-EOE and national income level, with 96 (31%) patients from LIC, 197 (6%) lower-middle income, 20 (2%) upper-middle income, and 6 (1%) patients from high-income countries (P = 0.0001). The outcomes were statistically significant for RB-EOE compared with RB-w/o-EOE: systemic metastasis (32% vs. 4% respectively; P = 0.0001) and metastasis-related death (63% vs. 6% respectively; P = 0.0001). Multimodal treatment was the most common form of treatment (n = 177; 54%) for RB-EOE, with most cases undergoing a combination of intravenous chemotherapy and enucleation (n = 97; 30%). Adjuvant external beam radiotherapy (EBRT) after surgery (enucleation/orbital exenteration) was given in only 68 (21%) cases. Kaplan–Meier analysis for systemic metastasis and metastasis-related death in RB-EOE was 28% and 57% at 1 year, 29% and 60% at 2 years, and 29% and 61% at 3 years, respectively. Cox regression analysis revealed that the risk of death from RB-EOE was greater in patients aged >4 years than

Published
2025
Full Text
View/download PDF

3. P1364: PHARMACOKINETIC PROFILE OF VARNIMCABTAGENE AUTOLEUCEL (IMN-003A), FIRST-IN-INDIA INDUSTRY CD19-DIRECTED CAR-T CELL THERAPY FOR PATIENTS WITH RELAPSED/ REFRACTORY B CELL MALIGNANCIES (IMAGINE STUDY)

Author

Pankaj Malhotra, Sunil Bhat, Sharat Damodar, Raja Thirumalairaj, Revathy Raj, Pooja Mallya, Akshatha Nayak, Ravi Joshi, Sudarshan Chougule, Deepak Mb, Sudeshna Dhar, Anne Roshan Joseph, Arun Kumar Mg, Jeetendra Kumar, Melina Soares, Sunil Yadav, Pallavi Arasu, Sri Ramulu Elluru, Mohammed Manzoor Akheel, Rahul Nahar, and Anil Kamat

Subjects
Diseases of the blood and blood-forming organs, RC633-647.5
Published
2023
Full Text
View/download PDF

4. P1409: PHASE-2 STUDY OF VARNIMCABTAGENE AUTOLEUCEL (IMN-003A) FIRST-IN-INDIA INDUSTRY CD19-DIRECTED CAR-T WITH FRACTIONATED INFUSIONS FOR PATIENTS WITH RELAPSED REFRACTORY B CELL MALIGNANCIES: IMAGINE STUDY

Author

Pankaj Malhotra, Sharat Damodar, Sunil Bhat, Raja Thirumalairaj, Revathy Raj, Akshatha Nayak, Pooja Mallya, Ravi Joshi, Deepak Mb, Sudarshan Chougule, Sudeshna Dhar, Arun Kumar Mg, Pallavi Arasu, Sri Ramulu Elluru, Mohammed Manzoor Akheel, and Anil Kamat

Subjects
Diseases of the blood and blood-forming organs, RC633-647.5
Published
2023
Full Text
View/download PDF

5. S245: RUXOLITINIB IN PEDIATRIC PATIENTS WITH TREATMENT-NAIVE OR STEROID-REFRACTORY CHRONIC GRAFT VERSUS HOST DISEASE: PRIMARY FINDINGS FROM THE PHASE II REACH5 STUDY

Author

Franco Locatelli, Bulent Antmen, Hyoung Jin Kang, Katsuyoshi Koh, Yoshiyuki Takahashi, Alphan Kupesiz, Maria Gabriela Matos, Donna Wall, Sunil Bhat, Ho Joon Im, Tayfun Gungor, Meng-Yao Lu, Tommaso Stefanelli, Christine Rosko, Annie St. Pierre, Karin Burock, and Cristina Diaz-De-Heredia

Subjects
Diseases of the blood and blood-forming organs, RC633-647.5
Published
2023
Full Text
View/download PDF

6. Outcomes of COVID-19 in children with cancer – Report from the Indian Pediatric Oncology Group (InPOG) COVID-19 registry in India

Author

Revathi Raj, Ramya Uppuluri, Badira Parambil, Nidhi Dhariwal, Sidharth Totadri, Leni Grace Mathew, Venkatraman Radhakrishnan, Abhishek Charan, Satya Prakash Yadav, Amita Mahajan, Sangeeta Mudaliar, Ratna Sharma, Mamta Manglani, Gaurav Kharya, Nishant Verma, Ramandeep Arora, Niharendu Ghara, Reghu KS, Nita Radhakrishnan, Nisha Iyer, Priti Mehta, Amitabh Singh, Shivani Patel, Joseph John, Sunil Bhat, Shobha Badiger, Sirisharani Siddaiahgari, Shruti Kakkar, Julius Scott, Dhaarani Jayaraman, Arathi Srinivasan, Yamini Krishnan, Ngangbam Sonamani, Ruchira Misra, Vibha Bafna, Rachna Seth, Purvi Kadakia Kutty, Swati Kanakia, Vasudha Rao, Anand Prakash, Vandana Bharadwaj, and Girish Chinnasamy

Subjects
Childhood cancer, COVID-19, Survival, Immunocompromised, Pediatrics, RJ1-570
Abstract

Introduction: The clinical outcomes of COVID-19 infection in children with cancer have been variable worldwide. Therefore, we aimed to collect data from all regions in India through a national collaborative study and identify factors that cause mortality directly related to COVID-19 infection. Methods: Data was collected prospectively on children across India on cancer therapy and diagnosed with COVID-19 infections from 47 centers from April 2020 to October 2021. Information was recorded on the demographics, the number of children that required intervention, and the outcome of the infection. In addition, we analyzed the impact of the delta variant in 2021. Results: A total of 659 children were studied, of whom 64% were male and 36% were female. The data from the eastern region was sparse, and this was a collection bias. COVID-19 infection was predominantly seen in children less than five years. The delta variant had a higher impact in the southern region, and this was statistically significant. Of the 659 children, 30 children died (4.5%), however only 7 of the deaths were directly attributed to COVID-19 infection (1%). Conclusion: The study reports the largest nationally representative cohort of children with cancer and COVID-19 to date in India. We identified demographic and clinical factors associated with increased all-cause mortality in patients with cancer. Complete characterization of the cohort has provided further insights into the effects of COVID-19 on cancer outcomes. The low mortality allows us to recommend that specific cancer treatments be continued without delays in therapy.

Published
2022
Full Text
View/download PDF

7. Matched Unrelated Hematopoietic Stem Cell Transplant in Juvenile-Onset Krabbe's Disease

Author

Ruchira Misra, Sunil Bhat, Suhani Shah, Anaita Hegde, Hiren Panwala, and Divyata Hingwala

Subjects
early referral, hematopoietic stem cell transplant, leukodystrophy, matched unrelated donor, Pediatrics, RJ1-570
Abstract

Background: Krabbe's disease is a neurodegenerative condition caused by a deficiency of a lysosomal enzyme, galactocerebrosidase (GALC), found mainly in the brain. There are four variants based on the age of onset: Infantile, late infantile, juvenile, and adult. Hematopoietic stem cell transplants can be curative as the GALC-positive donor cells migrate to the brain and provide GALC, thus correcting the deficiency. However, this is most effective when performed in the asymptomatic or mildly symptomatic phase. Maximum experience is in infantile-onset disease. The types of transplants usually used are matched sibling donor transplant or umbilical cord blood transplant. Clinical Description: A 5-year-old girl, the only child of a nonconsanguineous marriage, presented with complaints of frequent falls and progressive visual deterioration for 2 months. After evaluation, the clinical phenotype was ascertained to be that of a juvenile-onset (>5 years) neurodegenerative disorder with neuro-axis involvement of the brain (predominantly, white motor involvement-because of gait abnormalities and visual involvement) and absence of organomegaly or any other systemic involvement. Krabbe's disease was suspected. Supportive evidence was found on neuroimaging and confirmed by a homozygous mutation in the GALC gene that was consistent with Krabbe's disease. Management: The patient was treated with a matched unrelated bone marrow transplant, a modality that is generally not used in the management of Krabbe's disease. The clinical, neurophysiological, and neuroradiological profiles are compared during a 2-year follow-up. Currently, 2 years' posttransplant, she has not deteriorated further neurologically, and though legally blind is attending a special school for the visually impaired and performing most activities of daily living independently. Conclusion: Early matched unrelated donor transplant can be beneficial in juvenile-onset Krabbe's disease.

Published
2022
Full Text
View/download PDF

8. The setting up and running of a children's activity group and learning centre for children with haematological and oncology conditions

Author

Rhea Daruvala, Valli Narasimha, Sandhya Sharad, Manjari Bhatnagar, Prem Kumar, and Sunil Bhat

Subjects
activity group, childhood cancer, education, psychological well being, Neoplasms. Tumors. Oncology. Including cancer and carcinogens, RC254-282
Abstract

Abstract Background Children diagnosed with haematological and oncology conditions spend long periods of time undergoing treatments in hospital. Treatments are intensive and may include combinations of chemotherapy, radiation, surgery and bone marrow transplants. This often means that they have prolonged hospital stays away from family, friends and familiar environments. Aim We aimed at starting an activity group and learning centre based in the hospital setting for children undergoing treatment for haematological and oncology conditions. Methods The activity group and learning centre was set up in a tertiary care hospital under the department of Paediatric Haematology, Oncology and Bone Marrow Transplantation with the support of a local NGO called ‘Samiksha Foundation’ in Bangalore, India. Children who participated in the programme engaged in learning through participation in the activity groups which engaged in academic and non‐academic activities. The activity group and learning centre was piloted in April and May of 2019. During the pilot sessions, 156 children participated in the group. Children of all ages were welcome to attend and were given activities based on their age and learning levels. Until March 2020, the group has seen over 600 children in attendance. Results This methods report examines various aspects of the activity group such as setting up of the activity groups, how they are run, the activities conducted in the groups and the effects the group has had on children and their families as reported by them while undergoing treatment. Conclusion The overall response to the activity groups was positive and widely accepted among our patient community. The intervention proved to be effective, easy to implement and relatively inexpensive. We hope that by sharing data from our centre, more paediatric units may be able to implement such groups for children.

Published
2022
Full Text
View/download PDF

9. Guidance for Pediatric Hematology-Oncology (PHO) and Hematopoietic Stem Cell Transplant Services during COVID-19 Pandemic: A Consensus Statement by PHO Chapter of Indian Academy of Pediatrics

Author

Intezar Mehdi, Sunil Bhat, Mamta V. Manglani, Gaurav Narula, Ratna Sharma, Revathi Raj, Girish Chinnaswamy, Vikramjit Kanwar, Satyendra Katewa, and Satya Prakash Yadav

Subjects
Pediatric hematology-oncology, Hematopoietic stem cell transplant, Covid-19, India, Pediatrics, RJ1-570
Abstract

With the recent Pandemic of Covid-19 affecting more than 180 countries across the globe, services to children with blood disorders and cancers are likely to be affected. Children, in general, are at lesser risk of developing severe diseases and mortality, and mostly recover from it; fortunately, till date, very few cases have been reported in children with cancers. However, since this is an unprecedented pandemic, there is a felt need for guidance on the challenges faced in providing care to children with cancers and various blood disorders including those requiring Hematopoietic Stem Cell Transplantation (HSCT). This document will provide guidance on how to maintain continuity of care for children with blood disorders & cancers during the COVID-19 pandemic while exercising all precautions to reduce the risk of Covid-19 in this vulnerable group and if infected, what optimum care should be provided to these children.

Published
2020
Full Text
View/download PDF

15. Broken Rotor Bar Fault Diagnosis Techniques Based on Motor Current Signature Analysis for Induction Motor—A Review

Author

Sudip Halder, Sunil Bhat, Daria Zychma, and Pawel Sowa

Subjects
induction motor (IM), broken rotor bar (BRB), motor current signature analysis (MCSA), review, Technology
Abstract

The most often used motor in commercial drives is the induction motor. While the induction motor is operating, electrical, thermal, mechanical, magnetic, and environmental stresses can result in defects. Therefore, many researchers who are involved in condition monitoring have been interested in the development of reliable and efficient fault diagnostic technologies. This paper’s goal is to provide an overview of available fault detection methods for the broken rotor bar problem, one of several defects associated to induction motors. Despite the fact that it is less common than bearing or insulator failure, this fault may cause electrical machines to fail catastrophically. It can be quite harmful, especially in large motors, and it can develop as a result of manufacturing faults, repeated starting of the machine, mechanical stress, and thermal stress. Hence, a review on rotor defect diagnosis was conducted. In order to confirm rotor bar fracture, this research provides probable defect signatures that can be extracted from the current signal. Each defect signature is reported according to (a) loading level, (b) the number of BRBs, (c) validation, and (d) methodologies.

Published
2022
Full Text
View/download PDF

16. Ocular oncology practice guidelines during COVID-19 pandemic-An expert consensus

Author

Fairooz P Manjandavida, Santosh G Honavar, Usha Kim, Usha Singh, Vikas Menon, Sima Das, Swathi Kaliki, Mahesh Shanmugam Palanivelu, Vikas Khetan, Parag K Shah, Pukhraj Rishi, Kaustubh Mulay, Arpan Gandhi, B M Vadhiraja, Vijay Anand Reddy, Sunil Bhat, and Vasudha Rao

Subjects
covid-19, covid-19 guidelines, ocular malignancies, ocular oncology, ocular tumors, Ophthalmology, RE1-994
Abstract

The outbreak of rapidly spreading COVID-19 pandemic in December 2019 has witnessed a major transformation in the health care system worldwide. This has led to the re-organization of the specialty services for the effective utilization of available resources and ensuring the safety of patients and healthcare workers. Suspension of oncology services will have major implications on cancer care due to delayed diagnosis and treatment leading to irreversible adverse consequences. Therefore various oncology organizations have called for a continuation of cancer care during this crisis with diligence. The COVID-19 pandemic has forced the clinicians to transform the components of care from screening to outpatient care and primary management. The purpose of this article is to establish guidelines and recommendations for ocular oncology in the management of ocular tumors set by a multidisciplinary team of experts including ocular, medical and radiation oncologists, and pathologists. As the pandemic is evolving fast, it will require constant updates and reformation of health strategies and guidelines for safe and quality health care.

Published
2020
Full Text
View/download PDF

17. Mathematical Morphology-Based Feature-Extraction Technique for Detection and Classification of Faults on Power Transmission Line

Author

Revati Godse and Sunil Bhat

Subjects
Fault detection, fault classification, fault feature extraction, transmission line protection, decision tree, mathematical morphology, Electrical engineering. Electronics. Nuclear engineering, TK1-9971
Abstract

The permanency of highly-reliable power supply is a core trait of an electric power transmission network. A transmission line is the main part of this network through which power is transmitted to the utility. These lines are often damaged by accidental breakdowns owing to different random origins. Hence, researchers are trying to detect and identify these failures at the earliest to avoid financial losses. This paper offers a new real-time fast mathematical morphology-based fault feature extraction scheme for detection and classification of transmission line faults. The morphological median filter is exploited to wrest unique fault features which are then fed as an input to a decision tree classifier to classify the fault type. The acquired graphical and numerical results of the extracted features affirm the potency of the offered scheme. The proposed scheme is verified for different fault cases simulated on high-voltage transmission line modelled using ATP/EMTP with varying system constraints. The performance of the stated technique is also validated for fault detection and classification on real-field transmission lines. The results state that the proposed method is capable of detecting and classifying the faults with adequate precision and reduced computational intricacy, in less than a quarter of a cycle.

Published
2020
Full Text
View/download PDF

18. Fault Detection, Isolation and Service Restoration in Modern Power Distribution Systems: A Review

Author

Ishan Srivastava, Sunil Bhat, B. V. Surya Vardhan, and Neeraj Dhanraj Bokde

Subjects
distribution automation, reliability, service restoration, smart grid, multi-agent system, Technology
Abstract

This study examines the conceptual features of Fault Detection, Isolation, and Restoration (FDIR) following an outage in an electric distribution system.This paper starts with a discussion of the premise for distribution automation, including its features and the different challenges associated with its implementation in a smart grid paradigm. Then, this article explores various concepts, control schemes, and approaches related to FDIR. Service restoration is one of the main strategies for such distribution automation, through which the healthy section of the power distribution network is re-energized by changing the topology of the network. In a smart grid paradigm, the presence of intelligent electronic devices can facilitate the automatic implementation of the service restoration scheme. The concepts of service restoration and various approaches are thoroughly presented in this article. A comparison is made among various significant approaches reported for distribution automation. The outcome of our literature survey and scope for future research concludes this review.

Published
2022
Full Text
View/download PDF

19. Clinical and Molecular Findings in Mendelian Susceptibility to Mycobacterial Diseases: Experience From India

Author

Prasad D. Taur, Vijaya Gowri, Ambreen Abdulwahab Pandrowala, Vaishnavi V. Iyengar, Akshaya Chougule, Zainab Golwala, Shraddha Chandak, Reepa Agarwal, Purva Keni, Neha Dighe, Minnie Bodhanwala, Shakuntala Prabhu, Biju George, N. A. Fouzia, Eunice Sindhuvi Edison, Arun Kumar Arunachalam, Manisha Rajan Madkaikar, Aparna Dhondi Dalvi, Reetika Malik Yadav, Umair Ahmed Bargir, Priyanka Madhav Kambli, Amit Rawat, Jhumki Das, Vibhu Joshi, Rakesh Kumar Pilania, Ankur Kumar Jindal, Sunil Bhat, Sagar Bhattad, Jeeson Unni, Nita Radhakrishnan, Revathi Raj, Ramya Uppuluri, Shivani Patel, Harsha Prasada Lashkari, Amita Aggarwal, Manas Kalra, Zarir Udwadia, Vibha Sanjay Bafna, Tarun Kanade, Anne Puel, Jacinta Bustamante, Jean Laurent Casanova, and Mukesh M. Desai

Subjects
IL-12/IL-23/ISG15/IFN-γ axis, intracellular pathogens, BCG-osis, Mycobacterium tuberculosis complex, IL-12Rβ1 defect, anti-tubercular treatment, Immunologic diseases. Allergy, RC581-607
Abstract

Mendelian Susceptibility to Mycobacterial diseases (MSMD) are a group of innate immune defects with more than 17 genes and 32 clinical phenotypes identified. Defects in the IFN-γ mediated immunity lead to an increased susceptibility to intracellular pathogens like mycobacteria including attenuated Mycobacterium bovis-Bacillus Calmette-Guérin (BCG) vaccine strains and non-tuberculous environmental mycobacteria (NTM), Salmonella, fungi, parasites like Leishmania and some viruses, in otherwise healthy individuals. Mutations in the IL12RB1 gene are the commonest genetic defects identified. This retrospective study reports the clinical, immunological, and molecular characteristics of a cohort of 55 MSMD patients from 10 centers across India. Mycobacterial infection was confirmed by GeneXpert, Histopathology, and acid fast bacilli staining. Immunological workup included lymphocyte subset analysis, Nitro blue tetrazolium (NBT) test, immunoglobulin levels, and flow-cytometric evaluation of the IFN-γ mediated immunity. Genetic analysis was done by next generation sequencing (NGS). Disseminated BCG-osis was the commonest presenting manifestation (82%) with a median age of presentation of 6 months due to the practice of BCG vaccination at birth. This was followed by infection with Salmonella and non-typhi Salmonella (13%), Cytomegalovirus (CMV) (11%), Candida (7%), NTM (4%), and Histoplasma (2%). Thirty-six percent of patients in cohort were infected by more than one organism. This study is the largest cohort of MSMD patients reported from India to the best of our knowledge and we highlight the importance of work up for IL-12/IL-23/ISG15/IFN-γ circuit in all patients with BCG-osis and suspected MSMD irrespective of age.

Published
2021
Full Text
View/download PDF

20. Multicenter Outcome of Hematopoietic Stem Cell Transplantation for Primary Immune Deficiency Disorders in India

Author

Revathi Raj, Fouzia N. Aboobacker, Satya Prakash Yadav, Ramya Uppuluri, Sunil Bhat, Dharma Choudhry, Vikas Dua, Gaurav Kharya, Neha Rastogi, Mansi Sachdev, Vipin Khandelwal, Venkateswaran Swaminathan, Atish Bakane, Balasubramaniam Ramakrishnan, and Biju George

Subjects
hematopoietic stem cell transplant, primary immune deficiency, conditioning, India, haploidentical, Immunologic diseases. Allergy, RC581-607
Abstract

BackgroundHematopoietic stem cell transplantation (HSCT) is the curative option for many primary immune deficiency disorders (PID). In the last 5 years, increased awareness, availability of diagnostics based on flow cytometry, genetic testing, improved supportive care, use of reduced toxicity conditioning, and success of haploidentical donor HSCT have improved access to HSCT for children with PID in India. We present results on children with PID who underwent HSCT across India and the factors that influenced outcome.Patients and MethodsWe collected retrospective data on the outcome of HSCT for PID from seven centers. We analyzed the impact of the type of PID, conditioning regimen, time period of HSCT- before or after January 2016, graft versus host disease prophylaxis, cause of mortality and overall survival.ResultsA total of 228 children underwent HSCT for PID at a median age of 12 months (range, 1 to 220 months) with a median follow up of 14.4 months. Infants accounted for 51.3% of the cohort and the male female ratio was 3:1. SCID (25%) and HLH (25%) were the more frequent diagnoses. Matched family donor was available in 36.4% and 44.3% children had a haploidentical HSCT. Reduced and myeloablative conditioning regimens were used with 64% children receiving a treosulfan based conditioning regimen. Peripheral blood stem cells were the predominant graft source at 69.3%. The survival in infants (60.2%) was inferior to children aged over 1 year (75.7% p value = 0.01). Children with Wiskott Aldrich syndrome (74.3%) and chronic granulomatous disease (82.6%) had the best outcomes. The survival was superior in children receiving HSCT from a matched sibling (78%) versus an alternate donor HSCT (61% p value = 0.04). In the cohort transplanted after January 2016 survival improved from 26.8% to 77.5% (p value = 0.00). Infection remains the main cause of mortality at in over 50% children. The 5-year overall survival rate was 68%.ConclusionSurvival of children with PID undergoing HSCT in India has improved dramatically in last 5 years. Alternate donor HSCT is now feasible and has made a therapeutic option accessible to all children with PID.

Published
2021
Full Text
View/download PDF

21. A Novel Splice Site Mutation in IFNGR2 in Patients With Primary Immunodeficiency Exhibiting Susceptibility to Mycobacterial Diseases

Author

Aravind K. Bandari, Babylakshmi Muthusamy, Sunil Bhat, Periyasamy Govindaraj, Pavithra Rajagopalan, Aparna Dalvi, Siddharth Shankar, Remya Raja, Kavita S. Reddy, Manisha Madkaikar, and Akhilesh Pandey

Subjects
IFNGR2 deficiency, gene therapy, IFN gamma signaling, non-tuberculous mycobacteria, infection, immunodeficiency, Immunologic diseases. Allergy, RC581-607
Abstract

Primary immunodeficiency (PID) refers to a group of heterogeneous genetic disorders with a weakened immune system. Mendelian susceptibility to mycobacterial disease (MSMD) is a subset of PID in which patients exhibit defects in intrinsic and innate immunity. It is a rare congenital disorder characterized by severe and recurrent infections caused by weakly virulent mycobacteria or other environmental mycobacteria. Any delay in definitive diagnosis poses a major concern due to the confounding nature of infections and immune deficiencies. Here, we report the clinical, immunological, and genetic characteristics of two siblings (infants) with recurrent infections. There was a history of death of two other siblings in the family after BCG vaccination. Whole exome sequencing of the two affected surviving infants along with their consanguineous parents identified a novel, homozygous single nucleotide splice acceptor site variant in intron 2 of the interferon gamma receptor 2 (IFNGR2) gene. Sanger sequencing of DNA obtained from blood and fibroblasts confirmed the variant. The patients underwent bone marrow transplantation from their father as a donor. RT-PCR and Sanger sequencing of the cDNA of patients from blood samples after transplantation showed the expression of both wild type and mutant transcript expression of IFNGR2. To assess partial or complete expression of IFNGR2 mutant transcripts, fibroblasts were cultured from skin biopsies. RT-PCR and Sanger sequencing of cDNA obtained from patient fibroblasts revealed complete expression of mutant allele and acquisition of a cryptic splice acceptor site in exon 3 that resulted in deletion of 9 nucleotides in exon 3. This led to an in-frame deletion of three amino acids p.(Thr70-Ser72) located in a fibronectin type III (FN3) domain in the extracellular region of IFNGR2. This illustrates individualized medicine enabled by next generation sequencing as identification of this mutation helped in the clinical diagnosis of MSMD in the infants as well as in choosing the most appropriate therapeutic option.

Published
2019
Full Text
View/download PDF

33. Retrospective analysis of 60 patients with Hemophagocytic Lymphohistiocytosis (HLH): focus on genetic variants associated with secondary/late onset disease

Author

Meeta Sunil, Chirantan Bose, Coral Karunakaran, Sunil Bhat, Nita Radhakrishnan, Srisha Rani, Saktivel Murugan, Ravi Gupta, Rohit Gupta, Mukesh Desai, and Arati Khanna- Gupta

Subjects
Biotechnology, TP248.13-248.65
Abstract

Hemophagocytic lymphohistiocytosis (HLH) is a rare disorder of uncontrolled cytotoxic T-lymphocyte and macrophage activation associated with extreme inflammation, which if left untreated is invariably fatal. HLH can be classified either as primary (familial) or secondary (acquired). Genetic mutations underlie primary HLH which typically occurs in young children, while secondary HLH is associated with infections, metabolic disease, and malignancies and manifests later in life. Both categories of HLH affect the function of T-lymphocytes and natural killer (NK) cells. Homozygous null mutations in several genes including PRF1, UNC13D (MUNC13-4), STX11, and STXBP2 (MUNC18-2) have been described in cases of primary HLH, where consanguinity has been shown to play a role. These mutations contribute to an uncontrolled inflammatory response, over production of interferon gamma (IFNγ) and pro-inflammatory cytokines leading to macrophage activation and eventually to tissue and organ damage. While no known genetic mutations have been described in patients with acquired HLH, an underlying genetic predisposition has been suggested. In an effort to better understand the genetic and clinical correlates of this disease, we performed retrospective analyses of 60 suspected HLH cases that were submitted by physicians for genomic analysis to our diagnostic laboratory. High throughput exome sequencing of the 60 HLH samples was carried out on an Illumina HiSeq 2500 platform, followed by bioinformatics analysis. Our data showed that 1) 34% of the patients had homozygous mutations in known HLH-associated genes, the majority of which were in the Perforin1 (PRF1) gene (70%) followed by mutations in the UNC13D (20%) and STXBP2 (10%) genes. Most patients with homozygous PRFI mutations were products of consanguineous marriages. The parents of these patients while being carriers, however, remained unaffected. 2) 18% of our patients had mutations in other congenital immune deficiency syndromes that are known to lead to HLH. 3) The remaining 48% of the patients lacked any known HLH-associated mutation. Our data suggest that heterozygous mutations in novel genes may contribute to predisposing patients to secondary HLH, particularly since most of these genes are associated with T-lymphocyte activation, which plays a vital role in the etiology of this devastating disease.

Published
2017
Full Text
View/download PDF

42. Impact of Conditioning Regimen and Graft-versus-Host Disease Prophylaxis on The Outcome of Haploidentical Peripheral Blood Stem Cell Transplantation for High-Risk Severe Aplastic Anaemia in Children and Young Adults: A Report from the Pediatric

Author

Gaurav Kharya, Sarita R. Jaiswal, Sunil Bhat, Revathi Raj, Satya P. Yadav, Vikas Dua, Santanu Sen, Atish Bakane, Shobha Badiger, Ramya Uppuluri, Neha Rastogi, Mansi Sachdev, Bharti Sharma, Ashraf Saifullah, and Suparno Chakrabarti

Subjects
Transplantation, Molecular Medicine, Immunology and Allergy, Cell Biology, Hematology
Abstract

Allogenic hematopoietic cell transplant (HCT) is the best curative approach patients with severe aplastic anemia (SAA). Outcome of HCT from haploidentical family donor (HFD) has improved, making it a feasible option for patients lacking HLA-identical donor. However, data on HFD-HCT for younger patients with SAA is sparse. In multicentre retrospective study, we report outcome of 79 patients undergoing HFD-HCT for SAA. All were heavily pre-transfused, median time to HCT12 months and 67% had failed previous therapies. Conditioning was based on Flu-Cy-ATG/TBI with or without thiotepa/melphalan (TT/Mel). Post-transplantation cyclophosphamide (PTCy) and CNI/Sirolimus were employed as GvHD prophylaxis with or without abatacept. Primary graft failure (PGF) was 16.43%, less in those conditioned with TT/Mel. Incidence of acute and chronic GVHD were 26.4% and 18.9%. At a median follow-up of 48 months, the overall survival (OS) and event free survival (EFS) were 61.6% and 58.1% respectively. Both OS/EFS were better in TT/Mel group and with abatacept as GVHD prophylaxis. On multivariate analysis, use of Abatacept was found to favourably impact the outcome variables including GVHD and EFS. Our study suggests that PTCy-based HFD-HCT is a reasonable option for young patients with high-risk SAA, where optimisation of conditioning and GVHD prophylaxis might improve outcomes further.

Published
2022

44. Property Evaluation of FML (Glare)

Author

Sunil Bhat, V. Ravinarayan, V.P. Kaushik, and H. Adarsha

Subjects
Property (philosophy), Materials science, Mechanics of Materials, business.industry, Mechanical Engineering, Glare (vision), General Materials Science, Direct shear test, Structural engineering, Condensed Matter Physics, business
Abstract

Fiber metal laminate (Glare) made of 2014-T6 aerospace aluminum alloy sheets adhesively bonded with E-glass fiber based composite prepregs is investigated in the paper. The fabrication procedure of the laminate is explained. Chemical composition, macrostructure and residual stress of aluminum alloy are obtained. Mechanical properties of the laminate viz. tensile, flexural and shear strengths are measured.

Published
2021
Full Text
View/download PDF

45. Response, Peak and Persistence of Varnimcabtagene Autoleucel (IMN-003A), First-in-India Industry CD19-Directed CAR-T Cell Therapy, with Fractionated Infusions for Patients with Relapsed and/or Refractory B Cell Malignancies: Early Results (IMAGINE Study)

Author

Sunil Bhat, Sharat Damodar, Pooja Mallya, Akshatha Nayak, Ravi Joshi, Bharath Ram S, Sudarshan Chougule, Deepak MB, Gopinadh Jakka, Sudeshna Dhar, Anne Roshan Joseph, Arun Kumar MG, Murugan Palanisamy, Jeetendra Kumar, Melina Soares, Pallavi Arasu, Sri Ramulu Elluru, Mohammed Manzoor Akheel, and Anil Kamat

Subjects
Immunology, Cell Biology, Hematology, Biochemistry
Published
2022
Full Text
View/download PDF

46. Early Results from a Phase-2 Study of Varnimcabtagene Autoleucel (IMN-003A), a First-in-India Industry CD19-Directed CAR-T Cell Therapy with Fractionated Infusions for Patients with Relapsed and/or Refractory B Cell Malignancies (IMAGINE Study)

Author

Sharat Damodar, Sunil Bhat, Akshatha Nayak, Pooja Mallya, Bharath Ram S, Ravi Joshi, Deepak MB, Sudarshan Chougule, Anne Roshan Joseph, Gopinadh Jakka, Sudeshna Dhar, Arun Kumar MG, Murugan Palanisamy, Sri Ramulu Elluru, Mohammed Manzoor Akheel, Arun Anand, and Anil Kamat

Subjects
Immunology, Cell Biology, Hematology, Biochemistry
Published
2022
Full Text
View/download PDF

47. Isolated Infratemporal Fossa Desmoid Fibromatosis: A Rare Case Report and Review of Literature

Author

Abhimanyu Kadapathri, Ashwini Munnangi, Vidya Bhushan R, Trupti Kolur, Sunil Bhat, R. T. Rajeswarie, Narayana Subramanium, Vijay Pillai, and Vivek Shetty

Subjects
medicine.medical_specialty, business.industry, Infratemporal fossa, Desmoid fibromatosis, body regions, medicine.anatomical_structure, Otorhinolaryngology, Rare case, medicine, Head and neck surgery, Abdomen, Surgery, Radiology, business, Head and neck, Site of origin
Abstract

Desmoid fibromatosis (DF) arising from musculoaponeurotic structures rarely affects the head and neck region with the abdomen being the most common site of origin. These are benign tumors with locally infiltrative nature usually presenting as painless swellings that are rapidly growing. The infratemporal fossa DF is an extremely rare location with few clinical reports. This article discusses the management of a 2-year-old child with DF of the infratemporal fossa (ITF) along with literature review.

Published
2021
Full Text
View/download PDF

48. Studies on development of alumina and ceria coated magnesium AZ91 composite for enhanced properties

Author

H. Adarsha, J. Deepak, N.P. Ram Kumar, and Sunil Bhat

Subjects
010302 applied physics, Materials science, Scanning electron microscope, Alloy, Composite number, Metallurgy, 02 engineering and technology, engineering.material, 021001 nanoscience & nanotechnology, 01 natural sciences, Corrosion, Specific strength, Coating, 0103 physical sciences, engineering, 0210 nano-technology, Porosity, Castability
Abstract

Magnesium (Mg) alloys possess high usage prospects in various fields such as aerospace, electronics, automotive and biomedical sectors owing to properties such as excellent castability, high specific strength, low density etc. However, such materials are prone to corrosion and wear due to the heat produced in the areas of application. This paper addresses the usage of sol–gel-based technique to develop coatings made of Alumina (Al2O3) and Ceria (CeO2) over alloy Mg AZ91. These additive materials exhibit exceptional resistance to wear and corrosion. Further, the study investigates the role of CeO2 doping in Al2O3 coating. The surface properties are assessed using scanning electron microscope. Density, porosity, corrosion and thermal properties of the coating are measured and the feasibility of using sol–gel route for developing corrosion resistant coatings is examined.

Published
2021
Full Text
View/download PDF

49. Guidance for Pediatric Hematology-Oncology (PHO) and Hematopoietic Stem Cell Transplant Services during COVID-19 Pandemic: A Consensus Statement by PHO Chapter of Indian Academy of Pediatrics

Author

Revathi Raj, Sunil Bhat, Gaurav Narula, Satya Prakash Yadav, Intezar Mehdi, Mamta Manglani, Ratna Sharma, Girish Chinnaswamy, Satyendra Katewa, and Vikramjit S. Kanwar

Subjects
medicine.medical_specialty, 2019-20 coronavirus outbreak, Coronavirus disease 2019 (COVID-19), medicine.medical_treatment, Pediatric Hematology/Oncology, India, Hematopoietic stem cell transplantation, Article, 03 medical and health sciences, 0302 clinical medicine, Pandemic, medicine, Pediatrics, Perinatology, and Child Health, Intensive care medicine, business.industry, Pediatric hematology-oncology, lcsh:RJ1-570, Hematopoietic stem cell, lcsh:Pediatrics, Hematology, Blood Disorder, medicine.anatomical_structure, Oncology, 030220 oncology & carcinogenesis, Pediatrics, Perinatology and Child Health, Continuity of care, Hematopoietic stem cell transplant, business, Covid-19, 030215 immunology
Abstract

With the recent Pandemic of Covid-19 affecting more than 180 countries across the globe, services to children with blood disorders and cancers are likely to be affected. Children, in general, are at lesser risk of developing severe diseases and mortality, and mostly recover from it; fortunately, till date, very few cases have been reported in children with cancers. However, since this is an unprecedented pandemic, there is a felt need for guidance on the challenges faced in providing care to children with cancers and various blood disorders including those requiring Hematopoietic Stem Cell Transplantation (HSCT). This document will provide guidance on how to maintain continuity of care for children with blood disorders & cancers during the COVID-19 pandemic while exercising all precautions to reduce the risk of Covid-19 in this vulnerable group and if infected, what optimum care should be provided to these children.

Published
2020

50. Quantification of Liver Iron Overload: Correlation of MRI and Liver Tissue Biopsy in Pediatric Thalassemia Major Patients Undergoing Bone Marrow Transplant

Author

Shobha Badiger, Varun Bafna, K.S. Nataraj, Sunil Bhat, Vimal Raj, Sharat Damodar, and Vellaichamy M Annapandian

Subjects
Bone marrow transplant, medicine.medical_specialty, Liver Iron Concentration, Hematology, medicine.diagnostic_test, business.industry, Thalassemia, Magnetic resonance imaging, medicine.disease, Gastroenterology, In vivo, Liver tissue, Internal medicine, Biopsy, medicine, Original Article, business
Abstract

Determination of the magnitude of body iron stores helps to identify individuals at risk of iron-induced organ damage in Thalassemia patients. The most direct clinical method of measuring liver iron concentration (LIC) is through chemical analysis of needle biopsy specimens. Here we present a noninvasive method for the measurement of LIC in vivo using magnetic resonance imaging (MRI). Twenty-three pediatric Thalassemia major patients undergoing bone marrow transplantation at our centre were studied. All 23 patients had MRI T2* and R2* decay time for evaluation of LIC on a 1.5 Tesla MRI system followed by liver tissue biopsy for the assessment of iron concentration using an atomic absorption spectrometry. Simultaneously, serum ferritin levels were measured by enzymatic assay. We have correlated biopsy LIC with liver T2* and serum ferritin values with liver R2*. Of the 23 patients 11 were males, the mean age was 8.3 ± 3.7 years. The study results showed a significant correlation between biopsy LIC and liver T2* MRI (r = 0.768; p

Published
2020
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results